Buradasınız

Anasayfa » Content

Subklinik hipotiroidi kadınlarda dislipidemiye neden olmayabilir

Subclinical hypothyroidism may not cause dyslipidemia in female patients

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2010
DOI: 
doi:10.2399/tahd.10.162

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Objective: Thyroid hormone deficiency may contribute hyperlipi-demia via reduced lipid peroxidation. Therefore we aimed to investigate lipid parameters of euthyroid and subclinical hypothy-roid patients who were positive for thyroid autoantibodies. Methods: 42 female euthyroid patients (group1) (age: 37.2±7.2 years, body mass index (BMI): 24.2±2.9 kg/m2 ) and subclinical hypothyroid 50 female patients (group2) (age: 35.4±3.0 years, BMI: 24.1±3.0 kg/m2) with high level of thyroid antibodies, and euthyroid 72 women with normal levels of thyroid antibodies (group 3) (age: 37.8±10.5 years, BMI: 23.3±2.8kg/m2) without any metabolic diseases were included in the study. Results: Serum cholesterol(C) (total-C, low-density lipoprotein (LDL)-C, high-density lipoprotein (HDL)-C, non-HDL-C), triglyc-eride levels and total-C/HDL-C ratio were compared between group 1, 2 and 3. HDL-C level (mg/dl) of group 2 was significant¬ly lower than the other groups (65.4±13.5, 54.9±11.8, 62.2±4.6, p=0.002, respectively), and triglyceride (mg/dl) levels of group 2 were higher than group 1 (79.4±29.1, 114±59; p=0.017, respec¬tively). Total-C/HDL-C ratio of group 2 was significantly higher than the other groups (3.0±0.6, 3.4±0.7, 2.7±0.7; p=0.001, respectively). There were positive correlation between TSH and total-C/HDL-C ratio and negative correlation between TSH and HDL-C (r =0.265, p=0.023/r =-0.291, p=0.012) and between FT4 and total-C/HDL-C ratios (r=-0.233, p=0.046). Conclusions: Although lipid parameters of SH group were higher than the control group, they were in the target limits. It may be thought that subclinical hypothyroidism is not enuogh to cause dislypidemia. Our result may support the point that concomitant diseases should be followed up closely and treated in patients with SH.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Tiroid hormonu eksikliği lipid peroksidasyonunu azaltarak hiperlipidemiye yol açabilir. Bu nedenle antitiroid antikorları saptanan ötiroid ve subklinik hipotiroid (SH) kişilerin lipid parametrelerini sağlıklı bireylerle karşılaştırdık. Yöntem: Çalışma, tiroid antikoru yüksek 42 ötiroid kadın (1. grup) (yaş: 37.2±7.2, vücut kitle indeksi (VKİ): 24.2±2.9 kg/m2), tiroid antikoru yüksek 50 SH kadın (2. grup) (yaş: 35.4±3, VKİ: 24.1±3.0 kg/m2) ile herhangi bir metabolik hastalığı bulunmayan, tiroid anti¬koru negatif, 72 sağlıklı kadın (3. grup) (yaş: 37.8±10.5, (VKİ): 23.3±2.8kg/m2) ile yürütüldü. Serum örneklerinde kolesterol (K), düşük yoğunluklu lipoprotein (LDL-K), yüksek yoğunluklu lipoprotein (HDL)-K, non-HDL-K, trigliserid düzeyleri ve total-K /HDL-K oranlarına bakıldı. Bulgular: 2. grupta HDL-K (mg/dl) düzeyi diğer gruplardan istatis-tiki olarak anlamlı derecede düşük, (HDL-KGrup1=65.4±13.5, HDL-KGrup2=54.9±11.8, HDL-KGrup3=62.2±4.6, p=0.002), trigliserid (mg/dl) düzeyi 2. grupta 1. gruptan anlamlı derecede yüksekti; (trigliseridGrup1=79.4±29.1, trigliseridGrup2=114±59; p=0.017). To-tal-K/HDL-K oranı, 2. grupta diğer gruplardan belirgin olarak yük¬sekti (Total-K/HDL-KGrup1=3.0±0.6, Total-K/HDL-KGrup2=3.4±0.7, Total-K/HDL-KGrup3=2.7±0.7; p=0.001). TSH ile total-K/HDL-K ora¬nı arasında pozitif, TSH ile HDL-K düzeyi arasında negatif (r=0.265, p=0.023/r=-0.291, p=0.012), ST4 ile total-K /HDL-K oranı arasında negatif korelasyon saptandı (r=-0.233, p=0.046). Sonuç: Olguların lipid parametrelerinin ortalamaları kontrol gru¬bundan yüksek olmakla birlikte normal sınırlar içinde olmaları, tek başına SH'nin dislipidemi yapmayabileceğini düşündürmektedir. Bu bulgular ışığında, Subklinik hipotiroidide eşlik eden hastalıkla¬rın daha yakından izlenmesi ve tedavisi kalp-damar hastalıkların¬dan korunmada gerçekçi bir yaklaşım olabilir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_14_pp_162-166.pdf
  • 4
162-166
  • Turkish

REFERENCES

References: 

1. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001; 155: 195-200.
2. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid: thyroid deficiency in the Framingham study. Arch Intern Med 1985; 45: 1386-8.
3. Tunbridge WM, Evered DC, Hall R, ve ark. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol (Oxf) 1977; 7:
481-3.
4. Ayala AR, Danese MD, Ladenson PW. When to treat mild hypothy-
roidism. Endocrinol Metab Clin North Am 2000; 29: 399-415.
5. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dys¬function. Endocr Rev2008; 29: 76-131.
6. Surks MI, Ortiz E, Daniels GH, ve ark. Subclinical thyroid disease. scien¬tific review and guidelines for diagnosis and management. JAMA 2004;
291: 228-38.
7.
Yeşilkay
a E, Belen B, Bideci A, Çamurdan O, Boyraz M, Cinaz P. Kronik otoimmün tiroiditli çocuk ve ergenlerin klinik özellikleri. Gülhane Tıp Dergisi 2008; 50:147-50.
8.
Özat
a M. Tiroid Hastalıklarına Güncel Yaklaşım. 1. Baskı. İstanbul, Epsilon Yayınları, 2005;35.
9. Hollowell JG, Staehling NW, Flanders WD ve ark. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin EndocrinolMetab 2002; 87: 489-99.
10. Hayashi N, Tamaki N, Konishi J ve ark. Sonography of Hashimoto's thyroiditis. J Clin Ultrasound 1986; 14: 123-6.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition
Examination Survey. JAMA2002; 287: 356-9.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentra¬tion of low-density lipoprotein cholesterol in plasma, without use of the preparative ultrcentrifuge. Clin Chem 1972; 18: 499-502.
13. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol 2010;
52: 151-6.
14. Advin V. Subclinical hypothyroidism: deciding when to treat. Am Fam Physician 1998; 57: 776-80.
15. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007;
92: 4575-82.
16. Tagami T, Tamanaha T, Shimazu S ve ark. Lipid Profiles in the untreat¬ed patients with Hashimoto thyroiditis and the effects of thyroxine treat¬ment on subclinical hypothyroidism with Hashimoto thyroiditis. Endocr J
2010; 57: 253-8.
17. Erdal M, Sahin M, Saglam K ve ark. Increased serum chitotriosidase activity following restoration of euthyroidism in patients with subclinical
hypothyroidism. Intern Med2008; 47: 1309-14.
18. Onat A, Sansoy V, Uyarel H, Keleş İ, Hergenç G. Türklerde HDL-Kolesterol Düzeyleri, Çevresel Etkenler ve Metabolik Sendrom Kriterleri. Türk Kardiyol Dern Arş 2004; 32: 273-8.
19. Shivaraj G, Prakash BD, Sonal V, Shruthi K, Vinayak H, Avinash M. Thyroid function tests: a review. Eur Rev Med Pharmacol Sci 2009; 13: 341¬9.
20. Rigo JC, Vieira JL, Dalacorte RR, Reichert CL. Prevalence of metabolic syndrome in an elderly community: comparison between three diagnostic methods. Arq Bras Cardiol 2009; 93: 85-91.

Thank you for copying data from http://www.arastirmax.com